3.69
+0.17(+4.83%)
Currency In USD
Previous Close | 3.52 |
Open | 3.5 |
Day High | 3.71 |
Day Low | 3.44 |
52-Week High | 8.4 |
52-Week Low | 3.44 |
Volume | 1.01M |
Average Volume | 1.51M |
Market Cap | 393.33M |
PE | -3.58 |
EPS | -1.03 |
Moving Average 50 Days | 4.81 |
Moving Average 200 Days | 5.59 |
Change | 0.17 |
If you invested $1000 in Annexon, Inc. (ANNX) since IPO date, it would be worth $207.77 as of February 05, 2025 at a share price of $3.69. Whereas If you bought $1000 worth of Annexon, Inc. (ANNX) shares 3 years ago, it would be worth $476.74 as of February 05, 2025 at a share price of $3.69.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year
GlobeNewswire Inc.
Jan 13, 2025 1:00 PM GMT
ANX005 First Potential Targeted Therapy for Guillain-Barré Syndrome Advancing Towards 1H 2025 BLA Submission ANX007 First Potential Neuroprotective Therapy for Geographic Atrophy Expected to Complete Enrollment of Phase 3 ARCHER II Trial in 2H 2025 A
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones
GlobeNewswire Inc.
Jan 10, 2025 1:00 PM GMT
Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operationsBRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clini
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2025 1:00 PM GMT
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflamma